David James VanderWeele

Also affiliated with Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response”.

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2344

N/A

1.2DataRank · unranked

38 citations

Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino +20 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5107

N/A

0.241DataRank · unranked

4 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17046

N/A

0.104DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilušić +15 more

A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps607

N/A

0DataRank · unranked

11 citations

Ali Shilatifard, Stephen D. Miller, Alicia K. Morgans, David James VanderWeele, Masha Kocherginsky +2 more

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps274

N/A

0DataRank · unranked

1 citations

Vinay Sagar, Borko Jovanovic, Alicia K. Morgans, David James VanderWeele, David I. Quinn +4 more

Multiple primary prostate tumors with differential drug sensitivity.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.342

N/A

0DataRank · unranked

0 citations

Huihui Ye, Nicholas T. Terrigino, Nicole V. Carrabba, Rayann Atway, Shana Y. Trostel +14 more

Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy

European Urology(2021)10.1016/j.eururo.2021.03.009

N/A

0DataRank · unranked

74 citations

Huihui Ye, Fatima Karzai, Stephanie A. Harmon, Nicholas T. Terrigino, David James VanderWeele +23 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps194

N/A

0DataRank · unranked

5 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.084

N/A

0DataRank · unranked

1 citations

Masha Kocherginsky, Sabah Munir, Brenda Martone, Alicia K. Morgans, Walter M. Stadler +3 more

Smart Nanocarriers for the Targeted Delivery of Therapeutic Nucleic Acid for Cancer Immunotherapy

Pharmaceutics(2023)10.3390/pharmaceutics15061743

N/A

0DataRank · unranked

20 citations

Jochen H. Lorch, David James VanderWeele, Bin Zhang, Abu Baker

A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.506

N/A

0DataRank · unranked

7 citations

Masha Kocherginsky, Parminder Singh, Zin Myint, Di Jiang, Elizabeth Wulff‐Burchfield +5 more

Data from Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

(2023)10.1158/1078-0432.c.6530054

N/A

0DataRank · unranked

0 citations

Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino +20 more

Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-19-0936

N/A

0DataRank · unranked

54 citations

Berkley E. Gryder, Yen Thi Minh Nguyen, Aian Neil Alilin, Adlai R. Grayson, Wardah Bajwa +8 more

Data from Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

(2023)10.1158/1078-0432.c.6530054.v1

N/A

0DataRank · unranked

0 citations

Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino +20 more

A case report of multiple primary prostate tumors with differential drug sensitivity

Nature Communications(2020)10.1038/s41467-020-14657-7

N/A

0DataRank · unranked

40 citations

Stephanie A. Harmon, Nicholas T. Terrigino, Fatima Karzai, Peter A. Pinto, Ravi A. Madan +16 more

Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy

medRxiv(2020)10.1101/2020.09.29.20199711

N/A

0DataRank · unranked

12 citations

Huihui Ye, Fatima Karzai, Stephanie A. Harmon, Nicholas T. Terrigino, David James VanderWeele +23 more